Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus

Human Pathology

Volumn 40, Issue 11, 2009, Pages 1517-1527

  Walker, Francine ^a   Abramowitz, Laurent ^a   Benabderrahmane, Dalila ^a   Duval, Xavier ^a   Descatoire, Véronique ^a   Hénin, Dominique ^a   Lehy, Thérèse ^a   Aparicio, Thomas ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cell quantification; Immunocytochemistry; In situ techniques; Viruses

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P16; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANTIBODY LABELING; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CHROMOGEN IN SITU HYBRIDIZATION; CONDYLOMA ACUMINATUM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SEROLOGY; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 70349860264     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.05.010     Document Type: Article

References (35)

1. Abramowitz L., Benabderrahmane D., Ravaud P., et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 21 (2007) 1457-1465
2. Sobhani I., Vuagnat A., Walker F., et al. Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 120 (2001) 857-866
3. Sobhani I., Walker F., Roudot-Thoraval F., et al. Anal carcinoma: incidence and effect of cumulative infections. AIDS 18 (2004) 1561-1569
4. Sun X.W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., and Wright Jr. T.C. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337 (1997) 1343-1349
5. Kermorgant S., Aparicio T., Dessirier V., Lewin M.J., and Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 22 (2001) 1035-1042
6. Normanno N., Bianco C., Strizzi L., et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6 (2005) 243-257
7. Takahashi H., and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109 (2005) 227-241
8. Weidner K.M., Sachs M., and Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121 (1993) 145-154
9. Wey J.S., Fan F., Gray M.J., et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104 (2005) 427-438
10. Walker F., Kermorgant S., Daraï E., et al. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 9 (2003) 273-284
11. Gordon M.S., Mendelson D.S., and Sweeney C. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. J Clin Oncol 25 Part I. 18S (2008) 3551 (abstract)
12. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 (2007) 975-984
13. Alvarez G., Perry A., Tan B.R., and Wang H.L. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 19 (2006) 942-949
14. Lê L.H., Chetty R., and Moore M.J. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 124 (2005) 20-23
15. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
16. Ishizaki H., Tsunoda T., Wada S., Yamauchi M., Shibuya M., and Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12 (2006) 5841-5849
17. Bean S.M., Eltoum I., Horton D.K., Whitlow L., and Chhieng D.C. Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. Am J Surg Pathol 31 (2007) 555-561
18. Samama B., and Lipsker D. Boehm N: p16 expression in relation to human papillomavirus in anogenital lesions. Hum Pathol 37 (2006) 513-519
19. Palefsky J.M., Holly E.A., Hogeboom C.J., et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 314-319
20. Kato H., Yoshikawa M., Miyazaki T., et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 22 (2002) 3977-3984
21. Cavalot A., Martone T., Roggero N., Brondino G., Pagano M., and Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29 (2007) 655-664
22. Khan A.J., King B.L., Smith B.D., et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8 (2002) 540-548
23. Wei Q., Chen L., Sheng L., Nordgren H., Wester K., and Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31 (2007) 493-499
24. Fuchs I., Vorsteher N., Bühler H., et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 27 (2007) 959-963
25. Onn A., Correa A.M., Gilcrease M., et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10 (2004) 136-143
26. Tsiambas E., Stavrakis I., Lazaris A.C., Karameris A., and Patsouris E. Evaluation of epidermal growth factor receptor gene and chromosome 7 alterations in squamous cell carcinoma of the larynx, using chromogenic in situ hybridization on tissue microarrays. J Laryngol Otol 121 (2007) 563-570
27. Hanawa M., Suzuki S., Dobashi Y., et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118 (2006) 1173-1180
28. Dacic S., Flanagan M., Cieply K., et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 125 (2006) 860-865
29. Ngan H.Y., Cheung A.N., Liu S.S., Cheng D.K., Ng T.Y., and Wong L.C. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 22 (2001) 176-183
30. Moreira I.S., Fernandes P.A., and Ramos M.J. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem 7 (2007) 223-245
31. Montemurro F., Valabrega G., and Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7 (2007) 257-268
32. Morabito A., De Maio E., Di Maio M., Normanno N., and Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11 (2006) 753-764
33. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
34. Kim D., Gambhira R., Karanam B., et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 26 (2008) 351-360
35. Bourgault-Villada I., Moyal-Barracco M., Ziol M., et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res 64 (2004) 8761-8766